AXIM Biotechnologies, Inc. (AXIM)
| Market Cap | 53.83M |
| Revenue (ttm) | 293,462 |
| Net Income (ttm) | -5.45M |
| Shares Out | 123.50M |
| EPS (ttm) | -0.06 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 25 |
| Last Price | $0.4300 |
| Previous Close | $0.4300 |
| Change ($) | 0.0000 |
| Change (%) | 0.00% |
| Day's Open | 0.4300 |
| Day's Range | 0.4200 - 0.4799 |
| Day's Volume | 202,986 |
| 52-Week Range | 0.1 - 1.27 |
News
SAN DIEGO, Jan. 11, 2021 (GLOBE NEWSWIRE) -- AXIM ® Biotechnologies, Inc . (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting o...
About AXIM
AXIM Biotechnologies is a vertically integrated research and development company focused on changing diagnosis and treatment for oncology and SARS-CoV-2 (COVID-19). The company's NeuCovix is the rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells. It is developing rapid diagnostic tests for the early detection of cancer and proprietary small molecules drugs to treat cancer and block metastasis. The company was formerly known as Axim International Inc. ... [Read more...]
| Industry Biotechnology | Founded 2010 |
| CEO John W. Huemoeller II | Employees 4 |
| Stock Exchange OTCMKTS | Ticker Symbol AXIM |
Financial Performance
In 2019, AXIM's revenue was $799,483, an increase of 308.70% compared to the previous year's $195,614. Losses were -$6.45 million, -4.55% less than in 2018.